Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 11, 2015, Pages 1345-1354

  Benza, Raymond L ^a   Gomberg Maitland, Mardi ^b   Demarco, Teresa ^c   Frost, Adaani E ^d   Torbicki, Adam ^e   Langleben, David ^f   Pulido, Tomas ^g   Correa Jaque, Priscilla ^a   Passineau, Michael J ^a   Wiener, Howard W ^h   Tamari, Mayumi ⁱ   Hirota, Tomomitsu ⁱ   Kubo, Michiaki ⁱ   Tiwari, Hemant K ^j  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Medical Center of Postgraduate Education ECZ   (Poland)

^f MCGILL UNIVERSITY   (Canada)

^g NATIONAL HEART INSTITUTE   (Mexico)

^h Department of Epidemiology ^*  (Mexico)

ⁱ INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

Endothelin receptor antagonists; Pharmacogenetics; Polymorphisms; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; SITAXSENTAN; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST;

6 MINUTE WALK TEST; ADULT; ARTICLE; BORG DYSPNEA SCORE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN INTERACTION; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE ASSESSMENT; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; EXERCISE TEST; EXERCISE TOLERANCE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HYPERTENSION, PULMONARY; MIDDLE AGED; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIN-1; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84948994206     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201501-0196OC     Document Type: Article

References (82)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142: 448-456.
3. Michelakis ED. Pulmonary arterial hypertension: yesterday, today, tomorrow. Circ Res 2014;115:109-114.
4. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;188:639-646.
5. Wilkins MR, Wharton J, Gladwin MT. Update in pulmonary vascular diseases 2012. Am J Respir Crit Care Med 2013;188:23-28.
6. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012;40:1555-1565.
7. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-215.
8. Matsuura A, Yamochi W, Hirata K, Kawashima S, Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998;32: 89-95.
9. Peifley KA, Winkles JA. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun 1998;242:202-208.
10. Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalfe JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis 1990;85:257-262.
11. Yang Z, Krasnici N, Lüscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999;100:5-8.
12. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990;265:20555-20562.
13. Biasin V, Chwalek K, Wilhelm J, Best J, Marsh LM, Ghanim B, Klepetko W, Fink L, Schermuly RT, Weissmann N, et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. Int J Biochem Cell Biol 2014;54:137-148.
14. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
15. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, Temma S, Shirakami G, Imura H, Mikawa H. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991;84:2280-2285.
16. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-469.
17. Kawashiri SY, Ueki Y, Terada K, Yamasaki S, Aoyagi K, Kawakami A. Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatol Int 2014;34:221-225.
18. Yao AM, Hao YP, Zhang J, Sun XJ, Wang HY, Li B, Li JL. Changes in plasma levels of atrial natriuretic peptide, endothelin-1 and von Willebrand factor among newborns with persistent pulmonary hypertension [in Chinese]. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:718-722.
19. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26: 1581-1585.
20. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, et al.; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-818.
21. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(Suppl 25): D60-D72.
22. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014;172: 332-339.
23. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46: 529-535.
24. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
25. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117: 3010-3019.
26. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-249.
27. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
28. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012;141:20-26.
29. Brown MJ, Sharma P, Stevens PA. Association between diastolic blood pressure and variants of the endothelin-1 and endothelin-2 genes. J Cardiovasc Pharmacol 2000;35(Suppl 2): S41-S43.
30. Nicaud V, Poirier O, Behague I, Herrmann SM, Mallet C, Troesch A, Bouyer J, Evans A, Luc G, Ruidavets JB, et al. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Témoins sur l'Infarctus du Myocarde (ECTIM) Study. Am J Hypertens 1999;12: 304-310.
31. Herrmann S, Schmidt-Petersen K, Pfeifer J, Perrot A, Bit-Avragim N, Eichhorn C, Dietz R, Kreutz R, Paul M, Osterziel KJ. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2001;22:1948-1953.
32. Stevens PA, Brown MJ. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 1995;26: S9-S12.
33. Doaei S, Gholamalizadeh M. The association of genetic variations with sensitivity of blood pressure to dietary salt: a narrative literature review. ARYA Atheroscler 2014;10:169-174.
34. Thompson MD, Cole DE, Capra V, Siminovitch KA, Rovati GE, Burnham WM, Rana BK. Pharmacogenetics of the G protein-coupled receptors. Methods Mol Biol 2014;1175:189-242.
35. Thompson MD, Cole DE, Jose PA, Chidiac P. G protein-coupled receptor accessory proteins and signaling: pharmacogenomic insights. Methods Mol Biol 2014;1175:121-152.
36. Sandoval J, Torbicki A, Souza R, Ramírez A, Kurzyna M, Jardim C, Jerjes-Sánchez Díaz C, Teal SA, Hwang LJ, Pulido T; STRIDE-4 investigators. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 2012;25:33-39.
37. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008;134: 775-782.
38. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007;26:63-69.
39. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056.
40. Langleben D, Brock T, Dixon R, Barst R; STRIDE-1 study group. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004;44: S80-S84.
41. Nakajima M, Takahashi A, Tsuji T, Karasugi T, Baba H, Uchida K, Kawabata S, Okawa A, Shindo S, Takeuchi K, et al.; Genetic Study Group of Investigation Committee on Ossification of the Spinal Ligaments. A genome-wide association study identifies susceptibility loci for ossification of the posterior longitudinal ligament of the spine. Nat Genet 2014;46:1012-1016.
42. Matsuda K, Takahashi A, Middlebrooks CD, Obara W, Nasu Y, Inoue K, Tamura K, Yamasaki I, Naya Y, Tanikawa C, et al. Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum Mol Genet 2015;24: 1177-1184.
43. Laurie CC, Doheny KF, Mirel DB, Pugh EW, Bierut LJ, Bhangale T, Boehm F, Caporaso NE, Cornelis MC, Edenberg HJ, et al.; GENEVA Investigators. Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol 2010;34: 591-602.
44. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575.
45. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. Bioinformatics 2010;26:2867-2873.
46. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004;74:765-769.
47. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005;95: 221-227.
48. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186: 428-433.
49. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
50. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-172.
51. Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002;53:146-152.
52. Modarressi MH, Taylor KE, Wolfe J. Cloning, characterization, and mapping of the gene encoding the human G protein gamma 2 subunit. Biochem Biophys Res Commun 2000;272: 610-615.
53. Yajima I, Kumasaka MY, Tamura H, Ohgami N, Kato M. Functional analysis of GNG2 in human malignant melanoma cells. J Dermatol Sci 2012;68:172-178.
54. Yajima I, Kumasaka MY, Yamanoshita O, Zou C, Li X, Ohgami N, Kato M. GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity. Am J Cancer Res 2014;4: 182-188.
55. Yajima I, Kumasaka MY, Naito Y, Yoshikawa T, Takahashi H, Funasaka Y, Suzuki T, Kato M. Reduced GNG2 expression levels in mouse malignant melanomas and human melanoma cell lines. Am J Cancer Res 2012;2:322-329.
56. Leung T, Chen H, Stauffer AM, Giger KE, Sinha S, Horstick EJ, Humbert JE, Hansen CA, Robishaw JD. Zebrafish G protein gamma2 is required for VEGF signaling during angiogenesis. Blood 2006;108: 160-166.
57. Mulligan T, Farber SA. Central and C-terminal domains of heterotrimeric G protein gamma subunits differentially influence the signaling necessary for primordial germ cell migration. Cell Signal 2011;23:1617-1624.
58. Yang M, He RL, Benovic JL, Ye RD. b-Arrestin1 interacts with the G-protein subunits b1g2 and promotes b1g2-dependent Akt signalling for NF-kB activation. Biochem J 2009;417:287-296.
59. Shi CS, Lee SB, Sinnarajah S, Dessauer CW, Rhee SG, Kehrl JH. Regulator of G-protein signaling 3 (RGS3) inhibits Gbeta1gamma 2-induced inositol phosphate production, mitogen-activated protein kinase activation, and Akt activation. J Biol Chem 2001;276: 24293-24300.
60. Matimba A, Li F, Livshits A, Cartwright CS, Scully S, Fridley BL, Jenkins G, Batzler A, Wang L, Weinshilboum R, et al. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics 2014;15:433-447.
61. Peng J, Li YL, Shen YF, Wang Y, Xu NY. Molecular cloning and expression analysis of the GNAS gene in pig and porcine fibroblast cells. Genet Mol Res 2014;13:5463-5473.
62. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. Minireview: GNAS: Normal and abnormal functions. Endocrinology 2004;145: 5459-5464.
63. Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, Rechavi G, Galun E, Honigman A. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res 2004;64:1338-1346.
64. Follin-Arbelet V, Torgersen ML, Naderi EH, Misund K, Sundan A, Blomhoff HK. Death of multiple myeloma cells induced by cAMPsignaling involves downregulation of Mcl-1 via the JAK/STAT pathway. Cancer Lett 2013;335:323-331.
65. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, Galuppo V, Mendicino I, Sacco W, Aquila I, et al. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol 2009;297: H2015-H2025.
66. Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 2006;7:9.
67. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, Aoki M, Yamamoto K, Higaki J, Ogihara T. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000;35: 237-243.
68. Newby AC, Southgate KM, Assender JW. Inhibition of vascular smooth muscle cell proliferation by endothelium-dependent vasodilators. Herz 1992;17:291-299.
69. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: New insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol 2013;111(Suppl 5):1A-16A, quiz 17A-19A.
70. Olschewski H. Prostacyclins. Handbook Exp Pharmacol 2013;218: 177-198.
71. da Cunha JM, Rae GA, Ferreira SH, Cunha FdeQ. Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. Eur J Pharmacol 2004;501: 87-94.
72. Takano S, Fukasawa M, Maekawa S, Kadokura M, Miura M, Shindo H, Takahashi E, Sato T, Enomoto N. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One 2014;9: e98718.
73. Garcia-Murillas I, Sharpe R, Pearson A, Campbell J, Natrajan R, Ashworth A, Turner NC. An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. Oncogene 2014;33: 2478-2486.
74. Ikuta K, Seno H, Chiba T. Molecular changes leading to gastric cancer: a suggestion from rare-type gastric tumors with GNAS mutations. Gastroenterology 2014;146:1417-1418.
75. Turcic K, Tobar-Rubin R, Janevska D, Carroll J, Din E, Alvarez R, Haick J, Pals-Rylaarsdam R. Three intragenic suppressors of a GTPasedeficient allele of GNAS associated with McCune-Albright syndrome. J Mol Endocrinol 2014;52:321-331.
76. Narumi S, Matsuo K, Ishii T, Tanahashi Y, Hasegawa T. Quantitative and sensitive detection of GNAS mutations causing McCune- Albright syndrome with next generation sequencing. PLoS One 2013;8: e60525.
77. Hong W, Lin B, Zhang B, Mao W, Zhang Y. Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status [in Chinese]. Zhongguo Fei Ai Za Zhi 2014;17:321-326.
78. Alakus H, Bollschweiler E, Hölscher AH, Warnecke-Eberz U, Frazer KA, Harismendy O, Lowy AM, Mönig SP, Eberz PM, Maus M, et al. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy. Ann Surg Oncol 2014;21: 4375-4382.
79. Vaqué JP, Dorsam RT, Feng X, Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant A, Seeger MA, Ksander BR, Teramoto H, et al. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. Mol Cell 2013;49:94-108.
80. Rasheed SAK, Teo CR, Beillard EJ, Voorhoeve PM, Casey PJ. MicroRNA-182 and microRNA-200a control G-protein subunit a-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. J Biol Chem 2013;288:7986-7995.
81. Castellanos-Rubio A, Caja S, Irastorza I, Fernandez-Jimenez N, Plaza- Izurieta L, Vitoria JC, Maki M, Lindfors K, Bilbao JR. Angiogenesisrelated gene expression analysis in celiac disease. Autoimmunity 2012;45:264-270.
82. Germain M, Eyries M, Montani D, Poirier O, Girerd B, Dorfmüller P, Coulet F, Nadaud S, Maugenre S, Guignabert C, et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet 2013;45:518-521.